The Journal of Urology
Volume 182, Issue 6 , Pages 2670-2676 , December 2009

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

  • Matthew R. Smith

      Affiliations

    • Massachusetts General Hospital Cancer Center, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence: Massachusetts General Hospital Cancer Center, Yawkey 7038, 55 Fruit St., Boston, Massachusetts 02114 (telephone: 617-724-5257; FAX: 617-726-4899)
    • Supported by a National Institutes of Health K24 Midcareer Investigator Award (5K24CA121990-02) and grants from the Prostate Cancer Foundation.
    • Financial interest and/or other relationship with Amgen, GTx and Novartis.
    • ,
  • Fred Saad

      Affiliations

    • Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
    • Financial interest and/or other relationship with Amgen and Novartis.
    • ,
  • Blair Egerdie

      Affiliations

    • Urology Associates Urologic Medical Research, Kitchener, Ontario, Canada
    • Financial interest and/or other relationship with Amgen, Astellas, Bayer HealthCare, GlaxoSmithKline and Pfizer.
    • ,
  • Maciej Szwedowski

      Affiliations

    • Wojewódzkie Centrum Medyczne, Opole, Poland
    • Financial interest and/or other relationship with Amgen.
    • ,
  • Teuvo L.J. Tammela

      Affiliations

    • Tampere University Hospital, Tampere, Finland
    • Financial interest and/or other relationship with Amgen, Orion Pharma and Ferring.
    • ,
  • Chunlei Ke

      Affiliations

    • Amgen Inc., Thousand Oaks, California
    • Financial interest and/or other relationship with Amgen.
    • ,
  • Benjamin Z. Leder

      Affiliations

    • Endocrine Unit, Boston, Massachusetts
    • Financial interest and/or other relationship with Amgen and Novartis.
    • ,
  • Carsten Goessl

      Affiliations

    • Amgen Inc., Thousand Oaks, California
    • Financial interest and/or other relationship with Amgen.

Received 21 April 2009

References 

  1. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596
  2. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68
  3. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238
  4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103
  5. Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol. 1999;35:23
  6. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781
  7. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004;10:2705
  8. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154
  9. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948
  10. Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004;101:541
  11. Lee H, McGovern K, Finkelstein JS, et al. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104:1633
  12. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005
  13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165
  14. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875
  15. Smith MR, Egerdie B, HernándezToriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745
  16. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929
  17. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897
  18. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410
  19. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416
  20. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age (Early Postmenopausal Intervention Cohort Study Group). N Engl J Med. 1998;338:485

 Study received institutional review board approval.

 Supported by Amgen Inc., Thousand Oaks, California.

 Clinical Trial Registration NCT00089674 (www.clinicaltrials.gov).

 See Editorial on page 2557.

PII: S0022-5347(09)02070-9

doi: 10.1016/j.juro.2009.08.048

The Journal of Urology
Volume 182, Issue 6 , Pages 2670-2676 , December 2009

Article Tools

* Image Usage & Resolution